J&J Secures $500M R&D Pact for JNJ-4804, Reports 71% ORR for JNJ-1900 in NSCLC Trial
Summary
Johnson & Johnson has announced a $500 million R&D co-funding pact with Royalty Pharma for JNJ-4804, a Phase 2 dual IL-23/TNF co-antibody targeting inflammatory conditions. This funding, spread across 2026-2027, supports the development of a key pipeline asset. Additionally, the company reported positive early efficacy data for JNJ-1900 (NBTXR3) in a trial for stage III inoperable non-small cell lung cancer (NSCLC), showing a 71.4% overall response rate (ORR) and 100% disease control rate (DCR) among seven evaluable patients. These developments bolster J&J's pharmaceutical pipeline, providing external funding for a promising asset and demonstrating strong early clinical success for another. Traders will monitor further clinical trial progress for both assets and the financial implications of the co-funding agreement.
At the time of this announcement, JNJ was trading at $242.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $584.4B. The 52-week trading range was $141.50 to $251.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.